Screening of differentially expressed proteins from human esophageal cancer and esophageal tissues by two-dimensional difference gel electrophoresis and mass spectrometry.
- Author:
Zhi-yong HUANG
1
;
Gang XIONG
;
Jun ZHANG
;
Wu-jun WANG
Author Information
- Publication Type:Journal Article
- MeSH: Biomarkers, Tumor; genetics; metabolism; Early Diagnosis; Electrophoresis, Gel, Two-Dimensional; Esophageal Neoplasms; diagnosis; genetics; pathology; Esophagus; cytology; metabolism; pathology; Gene Expression Regulation, Neoplastic; Humans; Mass Spectrometry; Neoplasm Staging; Proteins; genetics; metabolism
- From: Journal of Southern Medical University 2007;27(9):1406-1409
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish two-dimensional electrophoresis profiles from human esophageal cancer tissue and paired normal esophageal tissue and identify differentially expressed proteins to identify the molecular markers for early-stage diagnosis.
METHODSThe total proteins of human esophageal cancer tissue and paired normal esophageal tissue were separated by immobilized pH gradient-based two-dimensional gel electrophoresis (2-DE). The 6 differentially expressed proteins were analyzed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The peptide mass fingerprintings (PMF) were identified by database searching. Six differentially expressed proteins were validated by RT-PCR.
RESULTSThe well-resolved, reproducible 2-DE patterns of esophageal cancer tissue and esophageal normal tissue were established. Using MALDI-TOF-MS technology, 6 differential protein spots were identified. Among them, the expressions of squamous cell carcinoma antigen 1 (SCCA1b), KRT4 and annexin A1 were downregulated and triosephosphate isomerase (TPI1), heat shock protein 27 (HSP27) and manganese superoxide dismutase (MnSOD) were upregulated in esophageal cancer tissues.
CONCLUSIONThe identification of differential expressed proteins in human esophageal cancer and normal tissue will be helpful for screening the biomarker for early-stage diagnosis.
